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Guidelines on systemic corticosteroids in chronic obstructive pulmonary disease (COPD) exacerbation rely on
studies that excluded patients requiring ventilatory support. Recent publication of studies including ICU patients
allows estimation of the level of evidence overall and in patients admitted to the ICU. We included RCTs
evaluating the efficacy and safety of systemic corticosteroids in COPD exacerbation, compared to placebo or
standard treatment. The effect size on treatment success was computed by a random effects model overall and
in subgroups of non-ICU and ICU patients. Effects on mortality and on the rate of adverse effects of corticosteroids
were also computed. Twelve RCTs (including 1,331 patients) were included. Pooled analysis showed a statistically
significant increase in the treatment success rate when using systemic corticosteroids: odds ratio (OR) = 1.72,
95% confidence interval (CI) = 1.15 to 2.57; p = 0.01. Subgroup analysis showed different patterns of effect in ICU
and non-ICU subpopulations: a non-significant difference of effect in the subgroup of ICU patients (OR = 1.34,
95% CI = 0.61 to 2.95; p = 0.46), whereas in the non-ICU patients, the effect was significant (OR = 1.87, 95% CI = 1.18
to 2.99; p = 0.01; p for interaction = 0.72). Among ICU patients, there was no difference in the success whether
patients were ventilated with tracheal intubation (OR = 1.85, 95% CI = 0.14 to 23.34; p = 0.63) or with non-invasive
ventilation (OR = 4.88, 95% CI = 0.31 to 75.81; p = 0.25). Overall, there was no difference in the mortality rate
between the steroid-treated group and controls: OR = 1.07, 95% CI = 0.67 to 1.71; p = 0.77. The rate of adverse events
increased significantly with corticosteroid administration (OR = 2.36, 95% CI = 1.67 to 3.33; p < 0.0001). In particular,
treatment with systemic corticosteroids significantly increased the risk of hyperglycemic episodes requiring initiation
or alteration of insulin therapy (OR = 2.96, 95% CI = 1.69 to 5; p < 0.0001). We found corticosteroids to be beneficial
in the whole population (non-critically ill and critically ill patients) in terms of treatment success rate. However,
subgroup analysis showed that this effect of corticosteroids was only observed in non-critically ill patients whereas
critically ill patients derived no benefit from systemic corticosteroids regardless of the chosen ventilatory mode
(invasive or non-invasive ventilation). Further analyses showed no effect on mortality of corticosteroids, but higher
side effects, such as hyperglycemic episodes requiring the initiation or alteration of insulin therapy.
Keywords: COPD; Exacerbation; Corticosteroids; Critical care* Correspondence: f.abroug@rns.tn
1ICU, Centre Hospitalier Universitaire Fatouma Bourguiba, Monastir 5000,
Tunisia
2Research Lab LR12SP15, Centre Hospitalier Universitaire Fatouma Bourguiba,
Monastir 5000, Tunisia
© 2014 Abroug et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited.
Abroug et al. Annals of Intensive Care 2014, 4:32 Page 2 of 11
http://www.annalsofintensivecare.com/content/4/1/32Review
Introduction
Chronic obstructive pulmonary disease (COPD) is a com-
mon disease characterized by progressive and incom-
pletely reversible chronic airflow obstruction associated
with an exaggerated inflammatory response to bacteria,
viruses, or pollutants [1]. COPD has become the third
leading cause of mortality worldwide, with attributable
yearly costs of no less than 50 billion $ in the United
States [2-4]. Approximately 60% of these expenditures
are dedicated to the management of exacerbations of
COPD [4]. COPD exacerbation is defined as an acute
event in which there is impairment of respiratory symp-
toms beyond the level of daily changes requiring an
alteration of the usual treatment [1]. Each patient expe-
riences a mean of two exacerbations per year, which are
linked to a steady decline in lung function, quality of
life, and life expectancy [5-7]. Exacerbation of COPD
is associated with an accentuation of systemic and local
inflammation [8-11]. In combination with inhaled bron-
chodilators, systemic corticosteroids are the corner-
stone of the first-line treatment of exacerbation of
COPD and are strongly recommended by current guide-
lines [12-17]. Yet, the optimal systemic corticosteroid
formulation (e.g., methylprednisolone or prednisone),
daily dose (moderate vs high), route of administration
(oral or intravenous), and treatment duration (5 to
15 days) are unclear [16,18-22]. This drug combination
improves symptoms and lung function and reduces the
duration of hospitalization [23]. However, systemic
corticosteroids do not affect mortality rate related to
COPD exacerbation and are associated with known
adverse effects including increased frequency of hyper-
glycemic episodes (up to five times compared to un-
treated patients) [15,16].
In addition, most studies supporting corticosteroid
treatment in COPD exacerbation have been conducted
outside the ICU and have deliberately excluded patients
with severe exacerbation requiring ventilatory support in
the ICU, making hazardous extrapolation of their results
to patients admitted to the ICU especially when we refer
to steroids’ side effects that are peculiar to critically ill
patients: ICU-related neuromyopathy, interference with
sepsis evolution, hyperglycemic accidents and their
impact on the length of ventilatory support, etc. [24,25].
Two recent studies dealing specifically with severe COPD
exacerbation requiring ventilatory support yielded conflict-
ing results. Nevertheless, despite being underpowered,
these newly published studies on ICU patients shed light
on the level of evidence surrounding corticosteroid treat-
ment in ICU patients with COPD exacerbation.
The aim of this systematic review with meta-analysis
of the literature is to measure the level of scientific evi-
dence on systemic corticosteroid treatment in the caseof exacerbation of COPD in general, with particular em-
phasis on critically ill patients admitted to the ICU, in
the light of recent publications on this issue.
Materials and methods
Search strategy and study selection
Pertinent studies were searched in MEDLINE, EMBASE,
CINAHL, CENTRAL, and Science Citation Index for RCTs
published up to 1 June 2014 with the following MeSH
terms: [‘adrenal cortex hormone’ or ‘steroid’ or ‘corticoster-
oid’ or ‘hydrocortisone’ or ‘prednisone’ or ‘prednisolone’ or
‘methylprednisolone’ or ‘dexamethasone’] AND [‘COPD’ or
‘chronic obstructive pulmonary disease’ or ‘lung disease, ob-
structive NOT asthma’] AND [‘exacerbation’ or ‘AECOPD’
or ‘emergency’]. We have also looked for studies in other
data sources such as reference reports, journal articles,
and abstracts of conferences and conducted a manual
search in journals.
Study selection
We included all randomized controlled clinical trials
designed to evaluate the efficacy and safety of systemic
corticosteroids, whether administered orally or paren-
terally, during acute exacerbations of chronic obstructive
pulmonary disease (AECOPD), compared to placebo or
standard treatment. Other treatments (e.g., bronchodila-
tors, antibiotics) administered concomitantly had to be
comparable between the two arms of studies. Included
studies involved patients seen in an outpatient setting,
patients in emergency consultation, or patients hospital-
ized in the pulmonology ward or intensive care units.
Patients included in these studies were adults aged 18
and older with COPD, with recent acute exacerbation
identified clinically by the modification of functional
signs of COPD according to the Anthonisen criteria
[26]: worsening of recent dyspnea, cough, and change in
the characteristics of sputum consisting in the increase
in sputum volume or its appearance.
Data extraction and study characteristics
Two independent evaluators (LOB, IO) selected studies
according to the inclusion criteria and extracted the inter-
vention in each study, the type of patients, the location of
the study, and the criteria for primary and secondary
endpoints. Disagreements were resolved by consensus.
The quality of included studies was assessed by the Jadad
scale [27], which assigns a score ranging from 0 to 5.
Data synthesis
In this meta-analysis, the primary endpoint was treat-
ment success, which had different definitions in the
included studies. In outpatients and in those admitted
to general wards, treatment was deemed successful on
the basis of clinical improvement that was assessed by a
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volume in 1 s (FEV1), improvement in blood gases, or
reduction in the duration of hospitalization. In studies
dealing with ICU patients under ventilatory support,
successful treatment was defined as the lack of need for
intubation in patients treated with non-invasively venti-
lated (NIV) patients and reduced mortality rate in inva-
sively (intubated) ventilated patients.
Secondary outcomes included mortality whenever re-
ported for both groups and the rate of adverse effects of
corticosteroids. For the study purpose, we considered the
following: overall side effects, hyperglycemic episodes
requiring the initiation or changing of current insulin
therapy, psychiatric disorders, infections occurring during
hospitalization, hypertensive episodes, and gastrointestinal
bleeding.
Statistical analysis
The meta-analysis was conducted using the Comprehen-
sive Meta-Analysis (CMA) program V2 software (Biostat,
Englewood, NJ, USA). This meta-analysis was conducted
in accordance with the recommendations of the Cochrane
group and the PRISMA guidelines.
For binary outcomes (treatment success, mortality,
and adverse effects of systemic corticosteroids), we re-
ported the outcome estimates as odds ratios (ORs) with
95% confidence intervals (CIs). Statistical significance
was set at p <0.05 for hypothesis testing and p <0.1 for
heterogeneity testing. We measured heterogeneity and
expressed it as I2, with suggested thresholds for low
(I2 = 25% to 49%), moderate (I2 = 50% to 74%), and high
(I2 ≥ 75%) values. We used a random effects model
which merges the studies and provides an assessment of
more conservative treatment effect when heterogeneity
is present or suspected. We made this choice because
of the obvious heterogeneity of the studies included in
the analysis.
To assess publication bias, we visually examined the
funnel plot for mortality and performed the Egger test of
the intercept which uses precision to predict the
standardized effect. All statistical tests were two-sided.
Two subgroup analyses were performed in this meta-
analysis: the first one compared the effect of systemic
corticosteroids in patients who were admitted to the
ICU compared to that in patients treated elsewhere. The
second subgroup analysis compared patients from the
ICU subgroup, according to the ventilatory mode: inva-
sive or non-invasive ventilation.
Results
Search results and trial characteristics
Literature search initially identified 1,156 citations; 5
items were added after consulting the bibliography of
previously published meta-analyses and journals. Amongthese studies, 29 were identified as related to the use of
corticosteroids during AECOPD. Ultimately, 17 studies
were excluded, and 12 were included with a total of
1,331 patients [23,28-38]. The selection process is illus-
trated by a flow chart (Figure 1). The main clinical char-
acteristics of included studies are depicted in Table 1.
All studies were randomized, controlled, double-blind
studies except that of Abroug et al. [38] which was a
randomized, controlled, open-label study including crit-
ically ill patients. All studies had a Jadad score ≥3.
Eighty-two percent of included patients (1,092/1,331)
were male, with a mean age of 66 ± 14 years. Smoking
was reported in seven studies. Overall, 47% of the in-
cluded patients were smoking more than ten pack-years.
The definition of AECOPD was based on clinical
symptoms or on the results of respiratory evaluation.
There was no difference in demographic characteris-
tics between the groups receiving systemic corticoste-
roids and the control groups regarding main clinical
characteristics (Table 1).
The administered corticosteroid regimen varied among
studies with different formulations, routes of administra-
tion, and duration of treatment which ranged from 1 to
57 days. The duration of patient follow-up and wards of
inclusion and management of patients were also variable
(outpatients, emergency department, respiratory ward,
or ICU) (Table 1). Criteria defining the success of
corticosteroid treatment were also variable (Table 1): this
encompassed the reduction in the length of hospital
stay, increased FEV in non-ICU patients, and decreased
intubation rate and mortality in ICU patients.
Adverse effects related to corticosteroid treatment
have been reported in eight studies with emphasis on
hyperglycemia, infections, hypertension, gastrointestinal
bleeding, and psychiatric symptoms.
Data analysis
Comparison of systemic corticosteroids’ efficacy involved
722 patients who received treatment and 609 controls.
Primary endpoint: treatment success Pooled analysis
shows a statistically significant increase in the treatment suc-
cess rate when using systemic corticosteroids: OR = 1.72,
95% CI = 1.15 to 2.57; p = 0.01 (Figure 2). Overall, hetero-
geneity was low (I2 = 36%). There was no obvious publica-
tion bias detected by visual inspection of the ‘funnel plot’
(Figure 3). The Egger test was also non-significant (regres-
sion intercept = 1.05, p = 0.18).
Subgroup analysis which compared studies that in-
cluded ICU patients vs studies that excluded ICU pa-
tients (non-ICU patients) showed different patterns of
effect in these two subpopulations: the effect of steroid
administration was not statistically significant in the sub-
group of ICU patients (OR = 1.34, 95% CI = 0.61 to 2.95;
Figure 1 Flow chart of the meta-analysis.
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the effect was significant and similar to what has been
observed in the entire analysis (OR = 1.87, 95% CI = 1.18
to 2.99; p = 0.01; z test for interaction = 0.36, p = 0.72)
(Figure 2).
Heterogeneity was high in the analysis involving critic-
ally ill patients (I2 = 77.4%), while it was low in studies
including non-ICU patients (I2 = 17.4%).
In order to explore the high heterogeneity observed in
studies that included ICU patients, we compared the
outcome in these patients according to the mechanical
ventilation modality (invasive vs non-invasive ventila-
tion). There was no difference in the effect thereof. The
odds ratio was 1.85, 95% CI = 0.14 to 23.34; p = 0.63,
for the group of patients ventilated invasively through
an endotracheal tube and 4.88, 95% CI = 0.31 to 75.81;
p = 0.25, for the NIV group.
Secondary criteria Mortality was analyzed in nine studies.
Overall, the mortality rates were not statistically different
between the steroid-treated group and controls: OR = 1.07,
95% CI = 0.67 to 1.71; p = 0.77; I2 = 0% (Figure 4).
For adverse effects, overall, seven studies reported the
rate of adverse events linked to treatment by systemiccorticosteroids and showed a significant increase in this
risk: OR = 2.36, 95% CI = 1.67 to 3.33; p <0.0001; I2 = 3%.
In particular, hyperglycemic episodes requiring initiation
or alteration of insulin therapy which were reported in
five studies were increased by corticosteroid administra-
tion: OR = 2.96, 95% CI = 1.69 to 5; p <0.0001; I2 = 22.7%
(Figure 5).
Discussion
The current meta-analysis shows that overall systemic
corticosteroid therapy increases the rate of success of
the treatment of patients with COPD exacerbation.
Stratified analysis according to the exacerbation severity
(severe hypercapnic exacerbation requiring ventilatory
support in the ICU, compared to exacerbations not
requiring ventilatory support) showed that this effect of
corticosteroids was only observed in non-critically ill
patients whereas critically ill patients derived no benefit
from systemic corticosteroids regardless of the chosen
ventilatory mode (invasive or non-invasive ventilation).
Further analyses showed no effect of corticosteroids
on mortality, but higher side effects, such as hyper-
glycemic episodes requiring the initiation or alteration of
insulin therapy.







Patient number Intervention Duration
(days)











61.5 ± 9.5 22/44 22/44 Methylprednisolone IV
0.5 mg/kg/6 h × 72 h
3 Improvement in lung function 5
Emerman 1989 [28] ED Clinical and
pulmonary
function
64.0 ± 7.8 52/96 44/96 Methylprednisolone IV
100 mg single injection
1 Improvement in lung function;
no need for hospitalization
5





66.0 ± 10.9 60/113 53/113 Hydrocortisone IV 100
mg/4 h × 4 days or until
discharge, then prednisolone
PO 40 mg/day × 4 days
8 Improvement in FEV1 at 6 h;
no relapse or ED visit
4
Thompson 1996 [31] Ambulatory Clinical 67.8 ± 8.6 13/27 14/27 Prednisone PO 60 mg/day ×
3 days followed by 40 mg/day ×
3 days, then 20 mg/day ×
3 days
9 Improvement in FEV1 at days
1, 3, and 10; improved blood
gases and clinical symptoms
5
Wood-Baker 1997 [32] Pulmonology
ward
Clinical 72 ± 6.3 12/38 13/38 (1) Prednisolone PO 2.5 mg/kg/
day × 3 days, then placebo ×
11 days
3 Improvement in lung function,




13/38 (2) Prednisolone PO 0.6 mg/kg/
day × 7 days, then 0.3 mg/kg/day
× 7 days
14 FEV1 at day 1 and at 6 weeks,
hospitalization duration, clinical
improvement







67.3 ± 8.4 29/56 27/56 Prednisone PO 30 mg/day × 14 days 14 Elapsed time until treatment
failure, improvement in FEV1,
hospitalization duration
5





67.7 ± 9.3 80/271 111/271 (1) Methylprednisolone IV 125 mg/6
h × 72 h followed by prednisone PO
60 mg/day with slow tapering for
54 days
57 Improvement in FEV1 and blood
gases at day 3, clinical improvement,
hospitalization duration
5
80/271 (2) Methylprednisolone IV 125 mg/6
h × 72 h followed by prednisone PO
60 mg/day with slow tapering for
12 days
15 Lack of relapse or rehospitalization,
improvement in FEV1, clinical
improvement and improvement
in life quality at day 10





70.4 ± 8.3 62/128 66/128 Prednisone PO 30 mg/12 h × 3 days,
then 40 mg/day × 7 days
10 Improvement in lung function,
blood gases, and reduction in
hospitalization duration
4
Aaron 2003 [35] Ambulatory Clinical 69.4 ± 10.8 74/147 73/147 Prednisone PO 40 mg/day × 10 days 10 I: no relapse or readmission, II:
improvement in FEV1, clinical




















Table 1 Patients characteristics and steroid regimen in the studies included in the meta-analysis (Continued)
Chen 2008 [36] Pulmonology
ward
Clinical 71.6 ± 7.3 44/130 43/130 (1) Prednisone PO 30 mg/day ×
7 days
7 Improvement in FEV1, blood
gases, hospitalization duration
5
43/130 (2) Prednisone PO 30 mg/day ×
10 days, then 15 mg/day × 4 days
14
Alia 2011 [37] ICU Clinical 68.4 ± 10.2 43/83 40/83 Methylprednisolone IV 0.5 mg/kg/6
h × 3 days, then 0.5/kg/12 h × 3 days
followed by 0.5 mg/kg/day × 4 days
10 Mechanical ventilation duration,
ICU stay, and intubation rate
5
Abroug 2014 [38] ICU Clinical 69.0 ± 6 111/217 106/217 Prednisone 1 mg/kg/day × 10 days
maximum or until discharge
10 Non-invasive ventilation success,
ICU mortality in intubated patients
3





















Study name Statistics for each study Success / Total Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value SCS Control
ICU Alia_2011 2.92 1.08 7.89 0.03 35 / 43 24 / 40
ICU Abroug_2013 0.83 0.44 1.54 0.55 82 / 111 82 / 106
ICU 1.34 0.61 2.95 0.46
Non-ICU Albert_1980 0.48 0.04 5.67 0.56 20 / 22 21 / 22
Non-ICU Emerman_1989 0.55 0.15 1.97 0.36 44 / 52 40 / 44
Non-ICU Bullard_1996 2.05 0.80 5.26 0.14 16 / 60 8 / 53
Non-ICU Thompson_1996 35.31 1.75 710.40 0.02 13 / 13 6 / 14
Non-ICU Wood-Baker_1997 5.33 0.51 56.24 0.16 12 / 13 9 / 13
Non-ICU Niewoehner_1999 1.66 0.97 2.85 0.06123 / 16074 / 111
Non-ICU Davies_1999 6.36 0.69 58.50 0.10 28 / 29 22 / 27
Non-ICU Maltais_2002 2.71 0.69 10.73 0.16 59 / 62 58 / 66
Non-ICU Aaron_2003 2.01 0.99 4.09 0.05 51 / 70 40 / 70
Non-ICU Chen_2008 1.60 0.52 4.95 0.41 79 / 87 37 / 43
Non-ICU 1.87 1.18 2.99 0.01
Overall 1.72 1.15 2.57 0.01
0.1 0.2 0.5 1 2 5 10
Favours Control Favours Steroids
ICU Studies 
n ICU Studies 
verall
Figure 2 Pooled subgroup analysis. Effects of corticosteroid treatment on the success rate inferred from all included studies and separately
for the groups of studies on ICU patients and on non-ICU patients. Gray squares represent odds ratios (ORs) in individual trials with the size
proportional to the weight of the study. The 95% confidence intervals (CIs) for individual trials are denoted by lines. The pooled subgroup
estimate of the effect is represented by the blue diamond (with a width proportional to the confidence interval), and the combined overall
effect is represented by the red diamond. The I2 test for heterogeneity was moderate overall (I2 = 36%), high in the analysis involving critically ill
patients (I2 = 77.4%), and low in studies including non-ICU patients (I2 = 17.4%). The z test for interaction between subgroups was 0.36 (p = 0.72).
The meta-analysis is performed by a random effects model.
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tration of systemic steroids to patients experiencing
COPD exacerbation whatever its severity. In fact, most
of the evidence stems from studies in which patients
were treated on an outpatient basis or hospitalized
outside ICUs. The most severe patients who are usually
admitted to ICUs and receive ventilatory support were
usually excluded. In addition, despite the lack of import-
ant statistical heterogeneity, the global analysis we have
conducted suffers probably from obvious clinical hetero-
geneity of included studies. This heterogeneity stems
from substantial differences in the steroid regimen ap-
plied in these studies, the studies’ setting (emergency
department, pulmonology ward, or ICU), differences in
success criteria, and the criteria used for COPD and
exacerbation. All these discrepancies might indeed intro-
duce bias to overall inferences from these studies. Sub-
stantial variation in corticosteroid regimen (daily dose,
treatment duration, route of administration) might have
impacted per se the rate of treatment success provided
that the chosen regimen is close to or far from the idealcorticosteroid regimen, which is not validated so far. In
addition, pooling the results of studies conducted in pa-
tients with various levels of severity (wards or ICU pa-
tients) did not take into account the relationship
between baseline severity and success rate. Moreover,
Bullard et al. and Chen et al. did not specifically exclude
asthmatics suggesting that if these patients have actually
been included, they could have better responses to ster-
oid treatment than the remaining study patients [30,36].
Moreover, the extrapolation to ICU patients of what
was observed in less severe patients should not be
straightforward since administration of systemic steroids
to ICU patients should outweigh the specific harm in-
curred by such treatment in critically ill patients (neuro-
myopathy, facilitation and worsening of sepsis, etc.).
Moreover, beneficial effects of corticosteroids reported
so far were inferred from the impact on outcomes which
should not be regarded as patient-centered. Indeed,
outcomes that were positively impacted by corticosteroid
treatment (lung function, hypoxemia, relapse rate) are
not those that one expects to alter in life-threatening
Figure 3 Funnel plot of SE by odds ratio. The Egger test was non-significant (regression intercept = 1.05, p = 0.18).
Abroug et al. Annals of Intensive Care 2014, 4:32 Page 8 of 11
http://www.annalsofintensivecare.com/content/4/1/32exacerbations. Outcomes such as non-invasive ventila-
tion failure, ICU mortality, MV duration, and length of
ICU stay are indeed more relevant to ICU patients.
As a matter of fact, we are today in a situation where
even the ‘equipoise’ surrounding the use of systemic
steroids in COPD exacerbation is questioned [39]. This
is suggested by reports from registries reflecting the
real-world practice. Lindenauer et al. reported that no
less than 76% patients treated for COPD exacerbation
outside the ICU received either a high (92%) or a
moderate (8%) dose of systemic steroids [20]. Examining
the same database, but focusing on patients who were
excluded from the Lindenauer study, namely patients
with severe COPD exacerbation who were admitted to
the ICU, Kiser et al. report that only 6% were not treated
by systemic steroids while 64% of the remaining received
a very high dose of steroids (i.e., >240 mg/day methyl-
prednisolone equivalent) [19]. Both analyses clearly show
that there is very little equipoise, if any, about the use of
systemic corticosteroids in COPD exacerbation whether
requiring mechanical ventilation or not. Hopefully, the
scientific evidence concerning specifically patients with
severe COPD exacerbation requiring ventilatory support
became recently available. Alia et al. and Abroug et al.
published two RCTs including ICU patients [37,38]. Thefirst one was a positive Spanish multicenter, randomized,
double-blinded study that included 83 patients, showing
a 1-day reduction in the duration of ICU hospitalization
[37]. The second study was an open-label study con-
ducted in two ICUs in Tunisia with the aim of evaluat-
ing the effect of a 10-day prednisone course on ICU
mortality [38]. This study was a negative one, failing at
demonstrating any beneficial effect of steroid treatment
on ICU mortality, length of mechanical ventilation, and
ICU stay. We cannot readily account for these conflict-
ing results, but there were substantial differences in the
use of non-invasive ventilation. NIV was more fre-
quently applied in the Abroug et al. study (76% vs 44%
in the Alia et al. study) [37,38]. Moreover, despite fairly
similar rates of NIV failure overall, these were not dis-
tributed similarly in the studies’ arms. While Abroug
et al. reported similar failure rates in both study groups
(16% and 13% in prednisone-treated and control groups,
respectively), Alia et al. reported a striking difference in
NIV failure rate which was 0% in the steroid treated
group and 37% in the control group [37,38]. Both rates
reported by Alia et al. seem overly shifted from rates
usually reported in the literature [40].
Noteworthy, both studies were also stopped before
completion of the inclusion of the planned sample size
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper
ratio limit limit p-Value SCS Control
Niewoehner_1999 4.72 1.59 14.02 0.01 24 / 160 4 / 111
Davies_1999 15.21 0.81 284.52 0.07 6 / 29 0 / 27
Maltais_2002 17.97 1.00 321.72 0.05 7 / 62 0 / 66
Alia_2011 2.61 1.03 6.63 0.04 20 / 43 10 / 40
Abroug_2013 1.99 1.15 3.45 0.01 55 / 111 35 / 106
2.96 1.69 5.19 0.00
0.1 0.2 0.5 1 2 5 10
Control Higher Steroid Higher
Figure 5 Hyperglycemic episodes.
Study name Statistics for each study Dead / Total Odds ratio and 95% CI
Odds Lower Upper
ratio limit limit p-Value SCS Control
Albert_1980 5.49 0.25121.18 0.28 2 / 22 0 / 22
Bullard_1996 1.34 0.22 8.36 0.75 3 / 60 2 / 53
Wood-Baker_1997 0.31 0.01 8.30 0.48 0 / 13 1 / 13
Niewoehner_1999 0.80 0.35 1.87 0.61 13 / 160 11 / 111
Davies_1999 0.93 0.06 15.62 0.96 1 / 29 1 / 27
Maltais_2002 3.24 0.13 81.13 0.47 1 / 62 0 / 66
Aaron_2003 2.03 0.18 22.91 0.57 2 / 70 1 / 70
Alia_2011 1.18 0.29 4.76 0.81 5 / 43 4 / 40
Abroug_2013 1.10 0.52 2.33 0.81 17 / 111 15 / 106
1.07 0.67 1.71 0.77
0.1 0.2 0.5 1 2 5 10
Control Higher Steroid Higher
Figure 4 Effect on mortality.
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et al. included 83 out of the 198 patients planned to
show a 1-day reduction in mechanical ventilation
duration [37]. On the other hand, out of 300 patients re-
quired to demonstrate a reduction by 12% in the abso-
lute rate of ICU mortality, Abroug et al. eventually
included only 217 patients [38]. This was due principally
to the fact that a large proportion of patients considered
for inclusion (up to half in each study) was already
treated by corticosteroids at ICU admission. Indeed, the
administration of corticosteroids prior to hospitalization
was so widespread that many patients were not eligible
for both RCTs, illustrating the difficulties in completing
such studies in the ICU. Despite apparently conflicting
results, both studies concluded that it would take up to
2,000 patients to uncover an impact on hard outcomes
such as ICU mortality, NIV failure, etc. So how can we
answer such questions in ICU patients in order to reach
a sufficient level of evidence? Systematic reviews and
meta-analytic techniques offer in this respect interesting
resources, especially through the stratification of the
analysis according to the type of patients whether treated
in or outside the ICU. The fact that recent publications on
the issue yielded conflicting results makes it very useful to
examine the trend from the pooled effects through meta-
analytic techniques. Previous meta-analyses included only
primary studies that were conducted in non-ICU patients.
Although systemic corticosteroids had no effect on mor-
tality, these meta-analyses showed that systemic cortico-
steroids yielded a statistically significant reduction in
treatment failure and/or relapse, improvement in FEV1,
and oxygenation [12,13,15-17]. The current meta-analysis
evaluated specifically the effect of systemic corticosteroids
in severe COPD exacerbation requiring ventilatory sup-
port. While the global analysis showed a favorable effect of
systemic corticosteroid therapy, subgroup analysis in the
subset of studies that included only patients requiring ven-
tilatory support reveals that available data synthesis did
not show any beneficial effect from systemic corticosteroid
treatment regarding either the rate of treatment success or
that of ICU mortality. Still, there are a 2.4-fold increase in
the adverse effects of steroid treatment overall and a
threefold increase in the hyperglycemic episodes. This
provides an additional argument which obviously weighs
negatively in the risk-benefit balance surrounding this
treatment. Nevertheless, absence of evidence of benefit
should not be regarded as evidence of the absence of corti-
costeroids’ benefit. The lack of a significant test for inter-
action means that our finding does not rule out the
possibility that this difference could be due to chance and
does not ascertain that systemic steroids have indeed an
opposite effect in ICU and non-ICU patients, especially
with the finding of inconsistent results in ICU studies
[41]. Moreover, the examination of the boundaries aroundthe estimation point in the present meta-analysis rules out
neither a deleterious effect of corticosteroids (39% risk of
a greater failure rate) nor an increase by threefold in the
success rate of corticosteroid treatment. A large study
including ICU patients is urgently needed in order to draw
a definitive conclusion in this subgroup of patients.
It may seem surprising that we advocate larger ran-
domized controlled trials on corticosteroids in this
population when the two available studies in critically ill
patients were early stopped because of recruitment
difficulties. We believe that the situation of equipoise
prevailing now is different from that prevailing before
the publication of the two RCTS on ICU patients and
the combined analysis made here. We should no longer
ignore the new evidence warning against potential dele-
terious effects of administering systemic corticosteroids
in COPD patients requiring ventilatory support [39].
Conclusions
This meta-analysis confirms that the rate of treatment
success increases with systemic corticosteroids in com-
parison to usual care in COPD exacerbation. Recent
publication of two RCTs dealing specifically with severe
exacerbations requiring ventilatory support allowed a
stratified analysis according to the necessity of ventila-
tory support in the ICU. For patients treated in the ICU,
there is no sufficient level of scientific evidence enabling
a strong recommendation. Current data cannot exclude
both possibilities: efficacy or inefficacy. Larger studies
targeting such patients are still needed.
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